TapewireFind a company

person · Reporting owner

SACHS BRUCE I

Disclosed activity across 1 company

Tapewire entity
14205
SEC CIK
0001197036

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875DirectorAugust 27, 2026August 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VERTEX PHARMACEUTICALS INC / MA

Report date August 27, 2026 · Filed August 31, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect39,000 Reported balance After 2026-08-27 transaction · row 1
1 source row

Row 1 · 2026-08-27 · Gift · Disposed 6,000 · Balance 39,000

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 27, 2026 Filed Aug 31, 2026 20:20 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GiftCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0000875320-26-000261 · wk-form4_1788207608.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Read SEC document
July 15, 2026 Filed Jul 17, 2026 20:06 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 99.941 $475.28 $47,499.96
Disclosure

SEC source: 0000875320-26-000249 · wk-form4_1784318797.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,771.807

Underlying: Common Stock · 99.941 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
May 01, 2026 Filed May 5, 2026 21:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 2,866 $0.00 Strike: $424.45 $0.00
Disclosure

SEC source: 0000875320-26-000187 · wk-form4_1778016282.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,866

Underlying: Common Stock · 2,866 shares

Expires 2036-04-30

F1 · derivative.exercise_date: Fully vested.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 107.345 $442.50 $47,500.16
Disclosure

SEC source: 0000875320-26-000161 · wk-form4_1776457052.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,671.866

Underlying: Common Stock · 107.345 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:45 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 107.088 $443.56 $47,499.95
Disclosure

SEC source: 0000875320-26-000006 · wk-form4_1768945505.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,564.521

Underlying: Common Stock · 107.088 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
October 15, 2025 Filed Oct 17, 2025 20:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 115.766 $410.31 $47,499.95
Disclosure

SEC source: 0000875320-25-000226 · wk-form4_1760731442.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,457.433

Underlying: Common Stock · 115.766 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
August 06, 2025 Filed Aug 7, 2025 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 PurchaseCommon Stock 3,366 $389.84 $1,312,201.44
Disclosure

SEC source: 0000875320-25-000218 · wk-form4_1754597921.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3 · price: Open market purchases reported on this line occurred at a weighted average price of $389.84 (range $389.61 to $390.00).

Read SEC document
August 06, 2025 Filed Aug 7, 2025 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 PurchaseCommon Stock 1,634 $389.36 $636,214.24
Disclosure

SEC source: 0000875320-25-000218 · wk-form4_1754597921.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,634

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $389.36 (range $388.61 to $389.60).

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

Read SEC document
July 15, 2025 Filed Jul 17, 2025 20:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 101.206 $469.34 $47,500.02
Disclosure

SEC source: 0000875320-25-000208 · wk-form4_1752782649.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,341.667

Underlying: Common Stock · 101.206 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
May 01, 2025 Filed May 5, 2025 20:55 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 2,398 $0.00 Strike: $502.97 $0.00
Disclosure

SEC source: 0000875320-25-000184 · wk-form4_1746478539.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,398

Underlying: Common Stock · 2,398 shares

Expires 2035-04-30

F1 · derivative.exercise_date: Fully vested.

Read SEC document
April 15, 2025 Filed Apr 17, 2025 20:07 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 95.475 $497.51 $47,499.77
Disclosure

SEC source: 0000875320-25-000164 · wk-form4_1744920427.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,240.461

Underlying: Common Stock · 95.475 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:04 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 111.654 $420.31 $46,929.29
Disclosure

SEC source: 0000875320-25-000002 · wk-form4_1737147865.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,144.986

Underlying: Common Stock · 111.654 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
October 15, 2024 Filed Oct 17, 2024 20:12 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 90.32 $484.39 $43,750.10
Disclosure

SEC source: 0000875320-24-000216 · wk-form4_1729195965.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,033.332

Underlying: Common Stock · 90.32 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
August 01, 2024 Filed Aug 2, 2024 20:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 5,295 $0.00 Strike: $125.71 $0.00
Disclosure

SEC source: 0000875320-24-000200 · wk-form4_1722629400.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,295 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
August 01, 2024 Filed Aug 2, 2024 20:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 5,295 $508.00 $2,689,860.00
Disclosure

SEC source: 0000875320-24-000200 · wk-form4_1722629400.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 02/12/2024.

Read SEC document
August 01, 2024 Filed Aug 2, 2024 20:10 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 5,295 $125.71 $665,634.45
Disclosure

SEC source: 0000875320-24-000200 · wk-form4_1722629400.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 15, 2024 Filed Jul 17, 2024 20:13 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 89.264 $490.12 $43,750.07
Disclosure

SEC source: 0000875320-24-000185 · wk-form4_1721247199.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,943.012

Underlying: Common Stock · 89.264 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
May 22, 2024 Filed May 24, 2024 20:13 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 7,073 $0.00 Strike: $93.51 $0.00
Disclosure

SEC source: 0000875320-24-000158 · wk-form4_1716581569.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,073 shares

Expires 2026-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
May 22, 2024 Filed May 24, 2024 20:13 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 7,073 $448.00 $3,168,704.00
Disclosure

SEC source: 0000875320-24-000158 · wk-form4_1716581569.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 02/12/2024.

Read SEC document
May 22, 2024 Filed May 24, 2024 20:13 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 7,073 $93.51 $661,396.23
Disclosure

SEC source: 0000875320-24-000158 · wk-form4_1716581569.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2024 Filed May 3, 2024 20:21 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 3,142 $0.00 Strike: $399.71 $0.00
Disclosure

SEC source: 0000875320-24-000129 · wk-form4_1714767664.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,142

Underlying: Common Stock · 3,142 shares

Expires 2034-04-30

F1 · derivative.exercise_date: Fully vested.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 20:07 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 109.49 $399.58 $43,750.01
Disclosure

SEC source: 0000875320-24-000115 · wk-form4_1713384457.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,853.748

Underlying: Common Stock · 109.49 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 12, 2024 Filed Jan 17, 2024 21:08 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 101.042 $432.99 $43,750.18
Disclosure

SEC source: 0000875320-24-000008 · wk-form4_1705525692.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,744.258

Underlying: Common Stock · 101.042 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
November 06, 2023 Filed Nov 8, 2023 21:11 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 11,250 $0.00 Strike: $127.54 $0.00
Disclosure

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
November 06, 2023 Filed Nov 8, 2023 21:11 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 11,250 $385.00 $4,331,250.00
Disclosure

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $385.00 (range $385.00 to $385.02).

Read SEC document
November 06, 2023 Filed Nov 8, 2023 21:11 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 11,250 $127.54 $1,434,825.00
Disclosure

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 20:19 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 118.25 $369.98 $43,750.14
Disclosure

SEC source: 0001209191-23-052961 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,643.216

Underlying: Common Stock · 118.25 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 11,250 $0.00 Strike: $127.54 $0.00
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · derivative · entry 6

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Fully vested.

Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 3,842 $357.29 $1,372,708.18
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $357.29 (range $357.00 to $357.38).

Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 5,711 $356.75 $2,037,399.25
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,842

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $356.75 (range $356.00 to $356.99).

Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 1,697 $355.54 $603,351.38
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,553

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $355.54 (range $355.00 to $355.97).

Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 11,250 $127.54 $1,434,825.00
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 14, 2023 Filed Jul 18, 2023 20:17 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 124.719 $350.79 $43,750.18
Disclosure

SEC source: 0001209191-23-042566 · doc4.xml · derivative · entry 5

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,524.966

Underlying: Common Stock · 124.719 shares

Expires not disclosed

F6 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F6 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F6 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
May 01, 2023 Filed May 3, 2023 21:05 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 3,481 $0.00 Strike: $342.73 $0.00
Disclosure

SEC source: 0001209191-23-027056 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,481

Underlying: Common Stock · 3,481 shares

Expires 2033-04-30

F1 · derivative.exercise_date: Fully vested.

Read SEC document
April 14, 2023 Filed Apr 18, 2023 21:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 131.473 $332.77 $43,750.27
Disclosure

SEC source: 0001209191-23-024711 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,400.247

Underlying: Common Stock · 131.473 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GiftCommon Stock 1,210 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 5

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 21,300 $0.00 Strike: $72.14 $0.00
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · derivative · entry 6

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,300 shares

Expires 2024-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully vested

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 8,026 $327.48 $2,628,354.48
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 10,357 $326.46 $3,381,146.22
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,236

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97).

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 2,917 $325.65 $949,921.05
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,593

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99).

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 21,300 $72.14 $1,536,582.00
Disclosure

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionStock Option (Right to Buy) · Derivative 1,200 $0.00 Strike: $72.14 $0.00
Disclosure

SEC source: 0001209191-23-006204 · doc4.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,300

Underlying: Common Stock · 1,200 shares

Expires 2024-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 SaleCommon Stock 1,200 $325.01 $390,012.00
Disclosure

SEC source: 0001209191-23-006204 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.01 (range $325.00 to $325.01).

Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:14 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 Exercise / conversionCommon Stock 1,200 $72.14 $86,568.00
Disclosure

SEC source: 0001209191-23-006204 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 13, 2023 Filed Jan 18, 2023 21:15 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 146.606 $298.42 $43,750.16
Disclosure

SEC source: 0001209191-23-003726 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,268.774

Underlying: Common Stock · 146.606 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
October 14, 2022 Filed Oct 18, 2022 20:27 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 147.396 $296.82 $43,750.08
Disclosure

SEC source: 0000899243-22-033744 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,122.168

Underlying: Common Stock · 147.396 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
July 15, 2022 Filed Jul 19, 2022 20:35 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 151.264 $289.23 $43,750.09
Disclosure

SEC source: 0000899243-22-026349 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,974.772

Underlying: Common Stock · 151.264 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
May 01, 2022 Filed May 3, 2022 20:43 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantStock Option (Right to Buy) · Derivative 4,462 $0.00 Strike: $276.17 $0.00
Disclosure

SEC source: 0000899243-22-016331 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,462

Underlying: Common Stock · 4,462 shares

Expires 2032-04-30

Read SEC document
April 14, 2022 Filed Apr 18, 2022 20:05 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 151.17 $289.41 $43,750.11
Disclosure

SEC source: 0000899243-22-014960 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,823.508

Underlying: Common Stock · 151.17 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document
January 14, 2022 Filed Jan 19, 2022 21:24 UTC VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 GrantDeferred Stock Units · Derivative 189.739 $230.58 $43,750.02
Disclosure

SEC source: 0001209191-22-003721 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,672.338

Underlying: Common Stock · 189.739 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.